Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PPD, Inc.
  6. News
  7. Summary
    PPD   US69355F1021

PPD, INC.

(PPD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PPD : Credit Suisse Downgrades PPD to Neutral from Outperform Following Proposed Sale to Thermo Fisher Scientific, Raises PT to $47.50 from $42

04/19/2021 | 09:22am EDT


© MT Newswires 2021
All news about PPD, INC.
07/29PPD : Management's Discussion and Analysis of Financial Condition and Results of..
AQ
07/28PPD : Q2 Results Increase from Year Ago
MT
07/28PPD : Reports Second Quarter and Year-To-Date 2021 Results (Form 8-K)
PU
07/28PPD : Earnings Flash (PPD) PPD Posts Q2 Revenue $1.58B
MT
07/28PPD : Earnings Flash (PPD) PPD Posts Q2 EPS $0.39
MT
07/28PPD : Reports Second Quarter and Year-To-Date 2021 Results
BU
07/28PPD, Inc. Announces Unaudited Consolidated Earnings Results for the Second Qu..
CI
07/28PPD, INC. : Results of Operations and Financial Condition, Financial Statements ..
AQ
07/20PPD : Recognized as a Best Place to Work in Asia
BU
07/12PPD : Announces Second Quarter 2021 Earnings Conference Call
BU
More news
Financials (USD)
Sales 2021 5 642 M - -
Net income 2021 329 M - -
Net Debt 2021 3 060 M - -
P/E ratio 2021 45,9x
Yield 2021 0,02%
Capitalization 16 203 M 16 203 M -
EV / Sales 2021 3,41x
EV / Sales 2022 3,12x
Nbr of Employees 28 000
Free-Float 61,4%
Chart PPD, INC.
Duration : Period :
PPD, Inc. Technical Analysis Chart | PPD | US69355F1021 | MarketScreener
Technical analysis trends PPD, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 46,12 $
Average target price 47,55 $
Spread / Average Target 3,09%
EPS Revisions
Managers and Directors
David S. Simmons Chairman & Chief Executive Officer
Christopher G. Scully CFO, Treasurer, Executive VP & Assistant Secretary
David Johnston Executive VP-Global Clinical Development
Karen Kaucic Chief Medical Officer & Executive Vice President
Rob Petrie Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
PPD, INC.34.78%16 203
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837